Medical device maker Verisante closes a $1.1 million prospectus offering , planning on using the funds to advance its Aura skin cancer detection technology.
Canada-based Verisante Technology (PINK:VRSEF) touted the close of its $1.1 million prospectus offering, raised through sales of common shares together with common share warrants at 19¢ per bundle.
The company plans to use the funds to advance its Aura skin cancer detection technology, including marketing, further development, manufacturing and pursuit of regulatory approval in the U.S. The funds will also go toward general and administrative costs, the company said.
